Customized phage therapies to eradicate
harmful bacteria in chronic diseases
We discover and validate proprietary bacterial targets, and develop rationally designed phage therapies that seek and destroy harmful bacteria in microbiome-related diseases such as inflammatory bowel disease (IBD) and cancer.
Our technology was developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science.
LEARN ABOUT OUR LEADERSHIPBiomX’s management and investors all have a long history of excellence that is propelling us to continued success and innovation.
LEARN ABOUT OUR BUSINESS LEADERSHIPOUR TECHNOLOGY
Our platforms use cutting edge computational and synthetic biology to discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets
Target Bacteria Discovery
Real time discovery of novel target bacteria through mining the extremely complex human microbiome
Phage Discovery
Develop customized phage therapies that seek and destroy harmful bacteria targets
Product Development
Proprietary assays, processes, and analyses to address pre-clinical and clinical needs, leading to commercialization
OUR INVESTORS
